中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 10
Oct.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(10): 2272-2276

Diagnosis and management of primary biliary cholangitis with osteoporosis

DOI: 10.3969/j.issn.1001-5256.2021.10.004

  • National Clinical Research Center for Digestive Diseases, Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

  • Received Date: 2021-08-10
  • Accepted Date: 2021-08-24
  • Published Date: 2021-10-20
    Abstract
  • Primary biliary cholangitis (PBC) is a chronic progressive cholestatic liver disease often observed in the middle-aged and elderly women and it can eventually lead to liver cirrhosis or liver failure. Osteoporosis is one of the common complications in PBC patients and is characterized by decreased bone mass and increased susceptibility to fractures. Osteoporosis and fractures caused by osteoporosis seriously affect the quality of life of PBC patients, and with the improvement of PBC treatment strategies and the increase in life expectancy, early diagnosis, prevention, and treatment of PBC with osteoporosis is of particular importance. This article briefly summarizes the epidemiology, pathogenesis, and diagnosis and treatment of patients with PBC and osteoporosis and proposes current challenges and future research directions.

     

    • FullText(HTML)
  • loading
    • References(39)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and management of primary biliary cirrhosis (cholangitis)(2015)[J]. J Clin Hepatol, 2015, 31(12): 1980-1988. DOI: 10.3969/j.issn.1001-5256.2015.12.004.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2015, 31(12): 1980-1988. DOI: 10.3969/j.issn.1001-5256.2015.12.004.
    [2]
    RUIZ-GASPÀ S, GUAÑABENS N, JURADO S, et al. Bile acids and bilirubin effects on osteoblastic gene profile. Implications in the pathogenesis of osteoporosis in liver diseases[J]. Gene, 2020, 725: 144167. DOI: 10.1016/j.gene.2019.144167.
    [3]
    Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the diagnosis and management of primary osteoporosis (2017)[J]. Chin J Osteoporosis, 2019, 25(3): 281-309. DOI: 10.3969/j.issn.1006-7108.2019.03.001.

    中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J]. 中国骨质疏松杂志, 2019, 25(3): 281-309. DOI: 10.3969/j.issn.1006-7108.2019.03.001.
    [4]
    DANFORD CJ, TRIVEDI HD, PAPAMICHAEL K, et al. Osteoporosis in primary biliary cholangitis[J]. World J Gastroenterol, 2018, 24(31): 3513-3520. DOI: 10.3748/wjg.v24.i31.3513.
    [5]
    GLASS LM, SU GL. Metabolic bone disease in primary biliary cirrhosis[J]. Gastroenterol Clin North Am, 2016, 45(2): 333-343. DOI: 10.1016/j.gtc.2016.02.009.
    [6]
    LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2019, 69(1): 394-419. DOI: 10.1002/hep.30145.
    [7]
    ZENG N, DUAN W, CHEN S, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: A systematic review and meta-analysis[J]. Hepatol Int, 2019, 13(6): 788-799. DOI: 10.1007/s12072-019-09984-x.
    [8]
    TRIVEDI HD, DANFORD CJ, GOYES D, et al. Osteoporosis in primary biliary cholangitis: Prevalence, impact and management challenges[J]. Clin Exp Gastroenterol, 2020, 13: 17-24. DOI: 10.2147/CEG.S204638.
    [9]
    MARTIN P, DIMARTINI A, FENG S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Hepatology, 2014, 59(3): 1144-1165. DOI: 10.1002/hep.26972.
    [10]
    DANFORD CJ, TRIVEDI HD, BONDER A. Bone health in patients with liver diseases[J]. J Clin Densitom, 2020, 23(2): 212-222. DOI: 10.1016/j.jocd.2019.01.004.
    [11]
    RUIZ-GASPÀ S, GUAÑABENS N, ENJUANES A, et al. Lithocholic acid downregulates vitamin D effects in human osteoblasts[J]. Eur J Clin Invest, 2010, 40(1): 25-34. DOI: 10.1111/j.1365-2362.2009.02230.x.
    [12]
    KAWELKE N, BENTMANN A, HACKL N, et al. Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation[J]. J Bone Miner Res, 2008, 23(8): 1278-1286. DOI: 10.1359/jbmr.080313.
    [13]
    RUIZ-GASPÀ S, GUAÑABENS N, JURADO S, et al. Bilirubin and bile acids in osteocytes and bone tissue. Potential role in the cholestatic-induced osteoporosis[J]. Liver Int, 2020, 40(11): 2767-2775. DOI: 10.1111/liv.14630.
    [14]
    CAO X. RANKL-RANK signaling regulates osteoblast differentiation and bone formation[J]. Bone Res, 2018, 6: 35. DOI: 10.1038/s41413-018-0040-9.
    [15]
    LIU W, ZHANG X. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review)[J]. Mol Med Rep, 2015, 11(5): 3212-3218. DOI: 10.3892/mmr.2015.3152.
    [16]
    SZALAY F, HEGEDUS D, LAKATOS PL, et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis[J]. J Hepatol, 2003, 38(4): 395-400. DOI: 10.1016/s0168-8278(02)00435-x.
    [17]
    FENG J, LIU S, MA S, et al. Protective effects of resveratrol on postmenopausal osteoporosis: Regulation of SIRT1-NF-κB signaling pathway[J]. Acta Biochim Biophys Sin (Shanghai), 2014, 46(12): 1024-1033. DOI: 10.1093/abbs/gmu103.
    [18]
    INVERNIZZI P, RANSOM M, RAYCHAUDHURI S, et al. Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis[J]. Genes Immun, 2012, 13(6): 461-468. DOI: 10.1038/gene.2012.17.
    [19]
    ESTRADA K, STYRKARSDOTTIR U, EVANGELOU E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture[J]. Nat Genet, 2012, 44(5): 491-501. DOI: 10.1038/ng.2249.
    [20]
    TANG R, WEI Y, LI Z, et al. A common variant in CLDN14 is associated with primary biliary cirrhosis and bone mineral density[J]. Sci Rep, 2016, 6: 19877. DOI: 10.1038/srep19877.
    [21]
    GUAÑABENS N, CERDÁ D, MONEGAL A, et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis[J]. Gastroenterology, 2010, 138(7): 2348-2356. DOI: 10.1053/j.gastro.2010.02.016.
    [22]
    KEMMLER W, ENGELKE K, VON STENGEL S. Long-term exercise and bone mineral density changes in postmenopausal women—are there periods of reduced effectiveness?[J]. J Bone Miner Res, 2016, 31(1): 215-222. DOI: 10.1002/jbmr.2608.
    [23]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease[J]. J Hepatol, 2019, 70(1): 172-193. DOI: 10.1016/j.jhep.2018.06.024.
    [24]
    WANG Z, PENG C, WANG P, et al. Serum vitamin D level is related to disease progression in primary biliary cholangitis[J]. Scand J Gastroenterol, 2020, 55(11): 1333-1340. DOI: 10.1080/00365521.2020.1829030.
    [25]
    EASTELL R, ROSEN CJ, BLACK DM, et al. Pharmacological management of osteoporosis in postmenopausal women: An endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2019, 104 (5): 1595-1622. DOI: 10.1210/jc.2019-00221.
    [26]
    SANTOS LA, ROMEIRO FG. Diagnosis and management of cirrhosis-related osteoporosis[J]. Biomed Res Int, 2016, 2016: 1423462. DOI: 10.1155/2016/1423462.
    [27]
    BENETTI A, CROSIGNANI A, VARENNA M, et al. Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: A controlled longitudinal study[J]. J Clin Gastroenterol, 2008, 42(3): 306-311. DOI: 10.1097/01.mcg.0000248017.31386.39.
    [28]
    KIM YH, JANG WG, OH SH, et al. Fenofibrate induces PPARα and BMP2 expression to stimulate osteoblast differentiation[J]. Biochem Biophys Res Commun, 2019, 520(2): 459-465. DOI: 10.1016/j.bbrc.2019.10.048.
    [29]
    ZHONG X, XIU LL, WEI GH, et al. Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation[J]. Acta Pharmacol Sin, 2011, 32(5): 591-600. DOI: 10.1038/aps.2011.15.
    [30]
    ZHONG X, XIU L, WEI G, et al. Bezafibrate prevents palmitate-induced apoptosis in osteoblastic MC3T3-E1 cells through the NF-κB signaling pathway[J]. Int J Mol Med, 2011, 28(4): 535-542. DOI: 10.3892/ijmm.2011.722.
    [31]
    NEVENS F, ANDREONE P, MAZZELLA G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J]. N Engl J Med, 2016, 375(7): 631-643. DOI: 10.1056/NEJMoa1509840.
    [32]
    RUDIC JS, GILJACA V, KRSTIC MN, et al. Bisphosphonates for osteoporosis in primary biliary cirrhosis[J]. Cochrane Database Syst Rev, 2011, (12): CD009144. DOI: 10.1002/14651858.CD009144.pub2.
    [33]
    GUAÑABENS N, MONEGAL A, CERDÁ D, et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis[J]. Hepatology, 2013, 58(6): 2070-2078. DOI: 10.1002/hep.26466.
    [34]
    TREEPRASERTSUK S, SILVEIRA MG, PETZ JL, et al. Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis[J]. Am J Ther, 2011, 18(5): 375-381. DOI: 10.1097/MJT.0b013e3181d7e1d3.
    [35]
    ORMARSDÓTTIR S, MALLMIN H, NAESSÉN T, et al. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis[J]. J Intern Med, 2004, 256(1): 63-69. DOI: 10.1111/j.1365-2796.2004.01342.x.
    [36]
    LEVY C, HARNOIS DM, ANGULO P, et al. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: Results of a pilot study[J]. Liver Int, 2005, 25(1): 117-121. DOI: 10.1111/j.1478-3231.2005.01026.x.
    [37]
    SUGIMOTO T. Anti-RANKL monoclonal antibody Denosumab (AMG162)[J]. Clin Calcium, 2011, 21(1): 46-51.
    [38]
    ARASE Y, TSURUYA K, HIROSE S, et al. Efficacy and safety of 3-year denosumab therapy for osteoporosis in patients with autoimmune liver diseases[J]. Hepatology, 2020, 71(2): 757-759. DOI: 10.1002/hep.30904.
    [39]
    DANFORD CJ, EZAZ G, TRIVEDI HD, et al. The pharmacologic management of osteoporosis in primary biliary cholangitis: A systematic review and meta-analysis[J]. J Clin Densitom, 2020, 23(2): 223-236. DOI: 10.1016/j.jocd.2019.05.003.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (584) PDF downloads(126) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return